TP53 and endometrial carcinoma: The discovery of good prognostic POLE mutations in endometrial endometrioid carcinomas (EECs) and the improvement of the surrogate immunohistochemical assay for poor prognostic p53 have great potential to refine the risk stratification of patients with endometrial carcinomas [1, 2, 3, 4].